First author | Year | Sex | Age at diagnosis (years) | Clinical conditions | Visceral KS localizations | Immunosuppression therapy | Tumor HHV8 status | Blood HHV8 status | KS management |
---|---|---|---|---|---|---|---|---|---|
Cohen | 2001 | F | 67 | Crohn disease | Ileum | Prednisone | ND | ND | Discontinuation of immunosuppressive therapy |
Kang | 2004 | F | 60 | Ulcerative colitis | Colon | Prednisone | + | ND | ND |
Nepomniashchaia | 2004 | M | 41 | Allogenic kidney transplantation | Stomach, intestinal mesentery, cerebral | ND | ND | ND | ND |
Bursics | 2005 | M | 49 | Ulcerative colitis | Colon | Methylprednisolone | − | − | Discontinuation of immunosuppressive therapy and coloprotectomy |
Svrcek | 2009 | M | 62 | Ulcerative colitis | Rectum | Steroid, azathioprine | + | + | Discontinuation of immunosuppressive therapy and coloprotectomy |
Girelli | 2009 | M | 43 | Ulcerative colitis | Descending colon | Prednisone, mesalazine, ciclosporin | + | − | Discontinuation of immunosuppressive therapy and coloprotectomy |
Rodriguez | 2010 | M | 65 | Ulcerative colitis | Colon | Prednisone, methotrexate | + | + | Discontinuation of immunosuppressive therapy and coloprotectomy |
Tas | 2012 | F | 77 | Chronic anemia | Colon, lymph nodes | None | + | ND | Etoposide |
Pioche | 2013 | M | 49 | Ulcerative colitis | Colon | Corticosteroids, azathioprine, ciclosporin, infliximab | + | + | Coloprotectomy |
Hamzaoui | 2013 | M | 30 | Ulcerative colitis | Colorectal | Prednisone, mesalazine, azathioprine, infliximab | + | ND | Subtotal colectomy |
Herculano | 2014 | M | 63 | Ulcerative colitis | Sigmoid colon | Prednisolone, mesalazine | + | − | Discontinuation of immunosuppressive therapy |
Windon | 2017 | M | 21 | Crohn disease | Colon | Prednisone, infliximab | − | − | Discontinuation of immunosuppressive therapy |
Duh | 2017 | M | 48 | Ulcerative colitis | Rectum | Prednisone | + | ND | Discontinuation of immunosuppressive therapy followed by subtotal colectomy |
Kumar | 2017 | M | 70 | Ulcerative colitis | Ascending colon | None | + | ND | ND |